Published in Eur Neuropsychopharmacol on April 03, 2013
Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry (2014) 2.18
Alcoholism risk reduction in France: a modernised approach related to alcohol misuse disorders. Int J Environ Res Public Health (2014) 1.39
Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil (2014) 1.10
Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol (2013) 1.05
Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing? Subst Abuse Rehabil (2015) 0.95
Clinical relevance of nalmefene versus placebo in alcohol treatment: Reduction in mortality risk. J Psychopharmacol (2015) 0.83
Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. Patient Prefer Adherence (2014) 0.81
Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol (2016) 0.80
A comparison of three types of web-based inhibition training for the reduction of alcohol consumption in problem drinkers: study protocol. BMC Public Health (2014) 0.80
Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis. J Addict Med (2015) 0.79
In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene. PLoS One (2015) 0.77
Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease. Biomolecules (2016) 0.77
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. PLoS One (2015) 0.77
Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry (2015) 0.76
Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs (2013) 0.76
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction (2016) 0.76
Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. World J Gastroenterol (2015) 0.76
Automatic Avoidance Tendencies for Alcohol Cues Predict Drinking After Detoxification Treatment in Alcohol Dependence. Psychol Addict Behav (2016) 0.75
Advances in alcoholic liver disease: An update on alcoholic hepatitis. World J Gastroenterol (2015) 0.75
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. Br J Clin Pharmacol (2016) 0.75
Evaluation in alcohol use disorders - insights from the nalmefene experience. BMC Med (2016) 0.75
The opioid receptors as targets for drug abuse medication. Br J Pharmacol (2015) 0.75
Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure. Int J Mol Sci (2016) 0.75
A prospective hospital study of alcohol use disorders, comorbid psychiatric conditions and withdrawal prognosis. Ann Gen Psychiatry (2016) 0.75
Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials. Patient Prefer Adherence (2016) 0.75
Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data. BMC Public Health (2015) 0.75
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood. Br J Pharmacol (2016) 0.75
Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Med (2017) 0.75
Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. PLoS One (2017) 0.75
Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA (2007) 6.81
A genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A (2010) 4.94
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci (2004) 3.56
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol (2008) 3.46
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry (2004) 2.84
Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl) (2004) 2.69
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med (2015) 2.33
Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction (2006) 2.23
A bibliometric analysis of European versus USA research in the field of addiction. Research on alcohol, narcotics, prescription drug abuse, tobacco and steroids 2001-2011. Eur Addict Res (2013) 2.22
Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction (2014) 2.16
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry (2012) 2.10
Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci (2005) 2.04
Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci (2012) 1.98
Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health (2002) 1.89
Should there be both categorical and dimensional criteria for the substance use disorders in DSM-V? Addiction (2006) 1.88
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A (2003) 1.88
Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Brain Res Cogn Brain Res (2005) 1.88
Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. J Psychopharmacol (2013) 1.79
Predictors of the 2-year recurrence and persistence of alcohol dependence. Addiction (2012) 1.78
The effect of computerized tailored brief advice on at-risk drinking in subcritically injured trauma patients. J Trauma (2006) 1.77
Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl) (2005) 1.76
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend (2005) 1.69
Structure of an O-GlcNAc transferase homolog provides insight into intracellular glycosylation. Nat Struct Mol Biol (2008) 1.66
Alcohol use disorders and the course of depressive and anxiety disorders. Br J Psychiatry (2012) 1.66
Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev (2009) 1.66
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Gender differences in the processing of standardized emotional visual stimuli in humans: a functional magnetic resonance imaging study. Neurosci Lett (2003) 1.63
Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry (2007) 1.62
Attentional bias predicts heroin relapse following treatment. Addiction (2006) 1.61
Alcohol and the human brain: a systematic review of different neuroimaging methods. Alcohol Clin Exp Res (2011) 1.60
Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. Biol Psychiatry (2012) 1.58
What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev (2003) 1.57
Risk taking and the adolescent reward system: a potential common link to substance abuse. Am J Psychiatry (2011) 1.56
Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology (2008) 1.56
Amygdala volume associated with alcohol abuse relapse and craving. Am J Psychiatry (2008) 1.56
SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry (2002) 1.54
Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. Am J Psychiatry (2005) 1.52
Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction (2010) 1.52
The place of additional individual psychotherapy in the treatment of alcoholism: a randomized controlled study in nonresponders to anticraving medication-results of the PREDICT study. Alcohol Clin Exp Res (2013) 1.52
Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol Psychiatry (2013) 1.49
Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction (2009) 1.46
Are scratchcards addictive? The prevalence of pathological scratchcard gambling among adult scratchcard buyers in the Netherlands. Addiction (2003) 1.46
Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nat Neurosci (2013) 1.45
Screening for Posttraumatic Stress Disorder: an evaluation of two self-report scales among crime victims. Psychol Assess (2003) 1.44
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry (2005) 1.41
Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage (2011) 1.41
Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health (2007) 1.40
Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol (2005) 1.39
Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry (2008) 1.39
Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction (2012) 1.39
Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster. Addict Biol (2011) 1.37
Brain activation elicited by affectively positive stimuli is associated with a lower risk of relapse in detoxified alcoholic subjects. Alcohol Clin Exp Res (2007) 1.37
Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend (2011) 1.36
Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol (2010) 1.36
Serotonin transporter genotype (5-HTTLPR): effects of neutral and undefined conditions on amygdala activation. Biol Psychiatry (2006) 1.35
Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med (2008) 1.34
The relationship between impulsive choice and impulsive action: a cross-species translational study. PLoS One (2012) 1.33
Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav (2002) 1.33
Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry (2012) 1.30
Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. Addict Biol (2010) 1.30
Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry (2005) 1.29
Properties of the Hopkins Symptom Checklist-25 (HSCL-25) and the Self-Reporting Questionnaire (SRQ-20) as screening instruments used in primary care in Afghanistan. Soc Psychiatry Psychiatr Epidemiol (2007) 1.29
The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci Lett (2006) 1.25
Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ (2005) 1.23
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med (2008) 1.23
Distorted expectancy coding in problem gambling: is the addictive in the anticipation? Biol Psychiatry (2012) 1.23
Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial. Biol Psychiatry (2011) 1.21
Cortisol moderates the relationship between testosterone and aggression in delinquent male adolescents. Biol Psychiatry (2006) 1.21
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med (2006) 1.21
Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab (2006) 1.21
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol (2006) 1.21
Dialectical Behavior Therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addict Behav (2002) 1.20
A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend (2004) 1.20
The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem (2007) 1.20
Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behav Res Ther (2005) 1.19
Ubiquitin binds to and regulates a subset of SH3 domains. Mol Cell (2007) 1.19
Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry (2011) 1.18
Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry (2010) 1.18
Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. Br J Clin Psychol (2006) 1.16
Psychiatric disorders in detained male adolescents: a systematic literature review. Can J Psychiatry (2010) 1.16
Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol (2003) 1.16
Comorbid psychopathology in adolescents and young adults treated for substance use disorders: a review. Eur Child Adolesc Psychiatry (2006) 1.16
Psychophysiological determinants and concomitants of deficient decision making in pathological gamblers. Drug Alcohol Depend (2006) 1.15
Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res (2010) 1.15
Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry (2009) 1.14
Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend (2008) 1.14
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) (2004) 1.13
Measuring craving: an attempt to connect subjective craving with cue reactivity. Alcohol Clin Exp Res (2006) 1.13
Alcoholism in women: is it different in onset and outcome compared to men? Eur Arch Psychiatry Clin Neurosci (2007) 1.13
Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study. Biol Psychiatry (2005) 1.13
Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry (2002) 1.13
Gender differences in the performance of a computerized version of the alcohol use disorders identification test in subcritically injured patients who are admitted to the emergency department. Alcohol Clin Exp Res (2004) 1.12
Neurophysiological evidence for abnormal cognitive processing of drug cues in heroin dependence. Psychopharmacology (Berl) (2003) 1.11
Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur J Neurosci (2006) 1.10
Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI. Alcohol Clin Exp Res (2006) 1.09
An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction (2002) 1.09
Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry (2007) 1.09